vs
Orthofix Medical Inc.（OFIX）与RAYONIER ADVANCED MATERIALS INC.（RYAM）财务数据对比。点击上方公司名可切换其他公司
RAYONIER ADVANCED MATERIALS INC.的季度营收约是Orthofix Medical Inc.的1.9倍（$417.5M vs $219.9M），Orthofix Medical Inc.净利率更高（-1.0% vs -5.0%，领先4.0%），Orthofix Medical Inc.同比增速更快（2.0% vs -1.2%），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs 3.8%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
RYAM（原雷尼尔先进材料公司）是一家美国全球性纤维素技术企业，主打高纯度特种纤维素产品，所生产的天然聚合物广泛应用于过滤器生产、食品加工、医药制造及各类工业领域，同时也为造纸和包装行业供应相关产品，在纤维素技术领域拥有较高的行业认可度。
OFIX vs RYAM — 直观对比
营收规模更大
RYAM
是对方的1.9倍
$219.9M
营收增速更快
OFIX
高出3.1%
-1.2%
净利率更高
OFIX
高出4.0%
-5.0%
两年增速更快
OFIX
近两年复合增速
3.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $417.5M |
| 净利润 | $-2.2M | $-21.1M |
| 毛利率 | 71.1% | 8.9% |
| 营业利润率 | 0.2% | 2.6% |
| 净利率 | -1.0% | -5.0% |
| 营收同比 | 2.0% | -1.2% |
| 净利润同比 | 92.4% | -31.9% |
| 每股收益（稀释后） | $-0.05 | $-0.33 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXRYAM
| Q4 25 | $219.9M | $417.5M | ||
| Q3 25 | $205.6M | $352.8M | ||
| Q2 25 | $203.1M | $340.0M | ||
| Q1 25 | $193.6M | $356.0M | ||
| Q4 24 | $215.7M | $422.5M | ||
| Q3 24 | $196.6M | $401.1M | ||
| Q2 24 | $198.6M | $419.0M | ||
| Q1 24 | $188.6M | $387.7M |
净利润OFIXRYAM
| Q4 25 | $-2.2M | $-21.1M | ||
| Q3 25 | $-22.8M | $-4.5M | ||
| Q2 25 | $-14.1M | $-363.2M | ||
| Q1 25 | $-53.1M | $-32.0M | ||
| Q4 24 | $-29.1M | $-16.0M | ||
| Q3 24 | $-27.4M | $-32.6M | ||
| Q2 24 | $-33.4M | $11.4M | ||
| Q1 24 | $-36.0M | $-1.6M |
毛利率OFIXRYAM
| Q4 25 | 71.1% | 8.9% | ||
| Q3 25 | 72.2% | 9.7% | ||
| Q2 25 | 68.7% | 7.0% | ||
| Q1 25 | 62.8% | 6.8% | ||
| Q4 24 | 69.0% | 8.7% | ||
| Q3 24 | 68.7% | 10.9% | ||
| Q2 24 | 67.8% | 11.5% | ||
| Q1 24 | 67.5% | 9.5% |
营业利润率OFIXRYAM
| Q4 25 | 0.2% | 2.6% | ||
| Q3 25 | -8.3% | 2.8% | ||
| Q2 25 | -7.9% | -0.4% | ||
| Q1 25 | -25.2% | -4.2% | ||
| Q4 24 | -5.3% | 2.6% | ||
| Q3 24 | -9.6% | -4.2% | ||
| Q2 24 | -12.5% | 6.7% | ||
| Q1 24 | -15.6% | 4.4% |
净利率OFIXRYAM
| Q4 25 | -1.0% | -5.0% | ||
| Q3 25 | -11.1% | -1.3% | ||
| Q2 25 | -6.9% | -106.8% | ||
| Q1 25 | -27.4% | -9.0% | ||
| Q4 24 | -13.5% | -3.8% | ||
| Q3 24 | -13.9% | -8.1% | ||
| Q2 24 | -16.8% | 2.7% | ||
| Q1 24 | -19.1% | -0.4% |
每股收益（稀释后）OFIXRYAM
| Q4 25 | $-0.05 | $-0.33 | ||
| Q3 25 | $-0.57 | $-0.07 | ||
| Q2 25 | $-0.36 | $-5.44 | ||
| Q1 25 | $-1.35 | $-0.49 | ||
| Q4 24 | $-0.76 | $-0.25 | ||
| Q3 24 | $-0.71 | $-0.49 | ||
| Q2 24 | $-0.88 | $0.17 | ||
| Q1 24 | $-0.95 | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | $75.4M |
| 总债务越低越好 | — | $758.1M |
| 股东权益账面价值 | $450.0M | $316.6M |
| 总资产 | $850.6M | $1.8B |
| 负债/权益比越低杠杆越低 | — | 2.39× |
8季度趋势，按日历期对齐
现金及短期投资OFIXRYAM
| Q4 25 | $82.0M | $75.4M | ||
| Q3 25 | $62.9M | $77.0M | ||
| Q2 25 | $65.6M | $70.7M | ||
| Q1 25 | $58.0M | $129.9M | ||
| Q4 24 | $83.2M | $125.2M | ||
| Q3 24 | $30.1M | $136.1M | ||
| Q2 24 | $26.4M | $114.1M | ||
| Q1 24 | $27.0M | $54.6M |
总债务OFIXRYAM
| Q4 25 | — | $758.1M | ||
| Q3 25 | $157.2M | $763.5M | ||
| Q2 25 | $157.0M | $720.4M | ||
| Q1 25 | $156.9M | $707.0M | ||
| Q4 24 | $157.0M | $706.4M | ||
| Q3 24 | $118.5M | $747.7M | ||
| Q2 24 | $118.0M | $752.8M | ||
| Q1 24 | $118.2M | $755.6M |
股东权益OFIXRYAM
| Q4 25 | $450.0M | $316.6M | ||
| Q3 25 | $442.5M | $338.2M | ||
| Q2 25 | $458.3M | $342.3M | ||
| Q1 25 | $458.3M | $688.1M | ||
| Q4 24 | $503.1M | $713.9M | ||
| Q3 24 | $525.9M | $732.7M | ||
| Q2 24 | $546.0M | $755.1M | ||
| Q1 24 | $570.3M | $741.8M |
总资产OFIXRYAM
| Q4 25 | $850.6M | $1.8B | ||
| Q3 25 | $832.6M | $1.8B | ||
| Q2 25 | $837.2M | $1.8B | ||
| Q1 25 | $823.1M | $2.1B | ||
| Q4 24 | $893.3M | $2.1B | ||
| Q3 24 | $867.9M | $2.2B | ||
| Q2 24 | $882.0M | $2.2B | ||
| Q1 24 | $906.0M | $2.1B |
负债/权益比OFIXRYAM
| Q4 25 | — | 2.39× | ||
| Q3 25 | 0.36× | 2.26× | ||
| Q2 25 | 0.34× | 2.10× | ||
| Q1 25 | 0.34× | 1.03× | ||
| Q4 24 | 0.31× | 0.99× | ||
| Q3 24 | 0.23× | 1.02× | ||
| Q2 24 | 0.22× | 1.00× | ||
| Q1 24 | 0.21× | 1.02× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | $32.3M |
| 自由现金流经营现金流 - 资本支出 | $16.8M | — |
| 自由现金流率自由现金流/营收 | 7.6% | — |
| 资本支出强度资本支出/营收 | 4.9% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-1.3M | — |
8季度趋势，按日历期对齐
经营现金流OFIXRYAM
| Q4 25 | $27.7M | $32.3M | ||
| Q3 25 | $12.4M | $-17.8M | ||
| Q2 25 | $11.6M | $-30.2M | ||
| Q1 25 | $-18.4M | $39.6M | ||
| Q4 24 | $23.7M | $54.9M | ||
| Q3 24 | $11.7M | $49.8M | ||
| Q2 24 | $9.0M | $87.6M | ||
| Q1 24 | $-18.6M | $11.3M |
自由现金流OFIXRYAM
| Q4 25 | $16.8M | — | ||
| Q3 25 | $2.5M | — | ||
| Q2 25 | $4.5M | — | ||
| Q1 25 | $-25.1M | — | ||
| Q4 24 | $15.2M | — | ||
| Q3 24 | $6.3M | — | ||
| Q2 24 | $-360.0K | — | ||
| Q1 24 | $-29.1M | — |
自由现金流率OFIXRYAM
| Q4 25 | 7.6% | — | ||
| Q3 25 | 1.2% | — | ||
| Q2 25 | 2.2% | — | ||
| Q1 25 | -13.0% | — | ||
| Q4 24 | 7.0% | — | ||
| Q3 24 | 3.2% | — | ||
| Q2 24 | -0.2% | — | ||
| Q1 24 | -15.4% | — |
资本支出强度OFIXRYAM
| Q4 25 | 4.9% | — | ||
| Q3 25 | 4.8% | — | ||
| Q2 25 | 3.5% | — | ||
| Q1 25 | 3.5% | — | ||
| Q4 24 | 4.0% | — | ||
| Q3 24 | 2.7% | — | ||
| Q2 24 | 4.7% | — | ||
| Q1 24 | 5.6% | — |
现金转化率OFIXRYAM
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 7.69× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
RYAM
| Cellulose Specialties | $249.6M | 60% |
| Other | $86.2M | 21% |
| Paperboard | $44.2M | 11% |
| High Yield Pulp | $28.3M | 7% |
| Biomaterials | $9.2M | 2% |
